History of Glucosamine: From Lobster Shells to the Supplement Aisle

Glucosamine began as a laboratory curiosity: a sugar with nitrogen in it, boiled out of crustacean shell in 1876. It took more than sixty years to pin down its exact shape, and longer still to learn that the human body makes it every day from glucose and glutamine. Then, in the space of a few decades, it became a prescription product in parts of Europe, one of the best-selling joint supplements in the United States, a tool that diabetes researchers used to cause insulin resistance in the lab, and the subject of large trials and guidelines that found it does little for joint pain. This page walks that history in order and ends with where the evidence stands now.

Table of Contents

  1. Overview: One Molecule, Three Careers
  2. Timeline at a Glance
  3. 1876: Ledderhose Boils Shell in Acid
  4. 1939: Haworth Settles Its Shape
  5. The Body Makes Its Own: GFAT and the Hexosamine Pathway
  6. A Pharmaceutical Form in Europe and the Absorption Studies
  7. The Late-1990s Supplement Boom in the United States
  8. 1991 Onward: A Glucose Sensor That Causes Insulin Resistance
  9. The Trial Era and the Guidelines: 2001 to 2020
  10. Worms, Mice and the UK Biobank Wave: 2014 to 2026
  11. 2026: Glucosamine Linked to Glucose Toxicity
  12. Where Things Stand Today
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Overview: One Molecule, Three Careers

Glucosamine is an amino sugar: a glucose molecule in which one oxygen-bearing group has been swapped for a nitrogen-bearing amino group. That small change makes it a building block for some of the most important structural molecules in nature. It is the repeating unit of chitin, the tough material in the shells of crabs, shrimp and lobsters and the walls of fungi, and in the human body it is the starting point for the long sugar chains that give cartilage, joint fluid and the lining of blood vessels their slippery, cushioning character.

Its history has three overlapping careers. The first is chemistry: isolating it, naming it, and working out its exact three-dimensional shape. The second is biochemistry: discovering that every cell can build glucosamine for itself from glucose, and that the pathway doing so acts as a sensor of how much sugar is flowing through the cell. The third is commerce and medicine: its rise as a joint remedy, the trials that tested that use, and a newer wave of large observational studies that keep finding associations nobody can yet explain.

Those careers collide in one place. The same pathway that makes glucosamine is the one diabetes researchers have spent thirty-five years studying as a cause of insulin resistance. That collision is why the research raises a concern about glucosamine supplements, most of all for people with diabetes or high blood sugar.

Back to Table of Contents

Timeline at a Glance

DateEvent
1876Georg Ledderhose, a German surgeon-chemist, reports glucosamine hydrochloride obtained by boiling chitin from crustacean shell in hydrochloric acid.
1880Ledderhose publishes a fuller paper on the substance.
1939Haworth, Lake and Peat establish the configuration of glucosamine, then also called chitosamine.
Mid-20th centuryBiochemists find that the body makes its own glucosamine through the enzyme GFAT (glucosamine-6-phosphate synthase), using glucose and glutamine.
Late 20th centuryA pharmaceutical crystalline form of glucosamine sulfate is used for osteoarthritis in parts of Europe; absorption studies follow.
1991Marshall and colleagues show that the glucosamine-making pathway mediates glucose-induced insulin resistance in fat cells, and that glucosamine itself is a far more potent trigger than glucose.
Late 1990sGlucosamine sales climb sharply in the United States after a best-selling popular book promotes it for arthritis.
2001Reginster trial reports less joint-space narrowing over 3 years with glucosamine sulfate. Setnikar review of absorption and metabolism.
2005Persiani pharmacokinetic study measures blood levels after oral doses in healthy volunteers.
2006GAIT, a large publicly funded US trial, finds glucosamine no better than placebo for knee pain overall.
2007Hart and colleagues review O-GlcNAc, the end product of the pathway, as a nutrient sensor with a role in diabetes.
2010Wandel network meta-analysis: no clinically relevant effect on joint pain or joint-space narrowing.
2014Weimer: glucosamine extends lifespan in worms and ageing mice.
2017Roman-Blas trial: glucosamine plus chondroitin no better than placebo for knee pain.
2019–2020OARSI (2019) and ACR/Arthritis Foundation (published 2020) osteoarthritis guidelines do not recommend glucosamine.
2019–2026UK Biobank observational studies link self-reported glucosamine use to lower heart disease, diabetes, death and albuminuria rates.
2026Riahi and colleagues link glucosamine made from excess glucose to glucose toxicity in pancreas and kidney.
2026Hawkinson and colleagues (Nature Metabolism) report that oral glucosamine worsened memory in Alzheimer's mice and that its use went with faster Alzheimer's progression in health records; a preprint re-check finds the same signal for other supplements. See Glucosamine and Alzheimer's Disease.

Back to Table of Contents

1876: Ledderhose Boils Shell in Acid

The story starts with the shells of crustaceans. Chemists of the 19th century already knew chitin as the hard, horn-like material of insect and crustacean skeletons, and they were curious what it was made of. In 1876 Georg Ledderhose, a German surgeon-chemist, reported that boiling chitin in strong hydrochloric acid broke it down into a crystalline salt. He called it "salzsaures Glycosamin" — glycosamine hydrochloride — in a short note in the Berichte der deutschen chemischen Gesellschaft, the leading German chemistry journal of the day.

The name told chemists what Ledderhose suspected: a sugar ("glycose", an old spelling of glucose) carrying an amine. Four years later, in 1880, he published a longer paper, "Ueber Glykosamin" ("On glycosamine"), in the Zeitschrift für physiologische Chemie, a journal devoted to the chemistry of living things.

That origin explains something many people still meet on supplement labels today: much commercial glucosamine is still made by breaking down shellfish shell, the same raw material Ledderhose used. Whether that matters for people with shellfish allergy is a separate question, covered on the Glucosamine Safety page.

Back to Table of Contents

1939: Haworth Settles Its Shape

Knowing that glucosamine was an amino sugar was not the same as knowing exactly which sugar it was. Sugars with the same atoms can differ only in the direction their groups point in space, and those differences decide how the body handles them. For decades the compound went by two names, glucosamine and chitosamine (after chitin), while chemists argued about its precise arrangement.

In 1939 the British chemist Walter Norman Haworth, with W. H. G. Lake and Stanley Peat, published "The configuration of glucosamine (chitosamine)" in the Journal of the Chemical Society. Their work settled that the molecule has the same spatial arrangement as glucose, with the amino group sitting where glucose carries a hydroxyl group at its second carbon — which is why the name glucosamine stuck.

Haworth was the obvious person for the job. Two years earlier he had shared the 1937 Nobel Prize in Chemistry for his work on the structure of carbohydrates and on vitamin C, and the ring-shaped drawings of sugars that every biology student learns are still called Haworth projections. The story of his vitamin C work is told on the History of Vitamin C page.

Back to Table of Contents

The Body Makes Its Own: GFAT and the Hexosamine Pathway

The most important discovery about glucosamine for anyone thinking of taking it came next: the body does not need it from food. In the middle of the 20th century, biochemists traced how cells build it themselves. A single enzyme, glutamine:fructose-6-phosphate amidotransferase — GFAT for short, also called glucosamine-6-phosphate synthase — takes a sugar made from glucose (fructose-6-phosphate) and an amino group taken from the amino acid glutamine, and joins them into glucosamine-6-phosphate.

A 2002 review by S. Milewski summed up what decades of work had shown. This enzyme catalyses the first committed step in the pathway that ends in a molecule called UDP-GlcNAc, the activated form of the sugar that cells use to build cartilage, mucus, joint fluid and the coatings of many proteins. Because it is the first committed step, GFAT is "an important point of metabolic control": it is where the cell decides how much glucose to send down this road. The same review noted that the enzyme is implicated in hexosamine-induced insulin resistance in diabetes — a thread picked up below.

So the human body runs its own glucosamine factory every day, fed by glucose and glutamine, with a gate at the entrance. The step-by-step chemistry, including the role of ATP, is laid out on How the Body Makes Glucosamine.

Back to Table of Contents

A Pharmaceutical Form in Europe and the Absorption Studies

In the second half of the 20th century, glucosamine moved from the chemistry bench to the pharmacy. In parts of Europe a crystalline form of glucosamine sulfate was developed and used as a medicine for osteoarthritis, the "wear-and-tear" joint disease. A drug needs evidence that it reaches the bloodstream, and two papers summarise that work.

In 2001 I. Setnikar and L. C. Rovati reviewed the absorption, distribution, metabolism and excretion of crystalline glucosamine sulfate in humans and animals. Using glucosamine tagged with a radioactive carbon tracer, they reported that at least 88.7% of an oral dose was absorbed from the gut in humans, but absolute oral bioavailability — how much reached the circulation intact enough to be counted — was about 44%. They attributed the difference largely to the liver handling much of it on its first pass. In rats and dogs, the tracer appeared in the liver, kidneys and other tissues, including joint cartilage.

In 2005 S. Persiani and colleagues gave 12 healthy volunteers once-daily doses of 750, 1,500 and 3,000 mg and measured glucosamine in their blood with a modern mass-spectrometry method. Two findings stand out. First, they detected glucosamine in the blood before any dose — the body's own supply. Second, the standard 1,500 mg dose raised plasma levels more than 30-fold above baseline, peaking at about 10 micromolar, and the response flattened at 3,000 mg. Both papers came from researchers working on that pharmaceutical form; later independent work, covered on the joint evidence page, asked whether those blood levels translate into benefit.

Back to Table of Contents

The Late-1990s Supplement Boom in the United States

In the United States glucosamine took a different route. Under the country's supplement law it could be sold over the counter as a dietary supplement rather than a prescription drug, without the approval process a medicine goes through. In the late 1990s demand rose sharply after a best-selling popular book promoted glucosamine, often paired with chondroitin, as a treatment for arthritis. Within a few years it was one of the most familiar products on supplement shelves, usually as glucosamine sulfate or glucosamine hydrochloride derived from shellfish shell.

That boom ran ahead of the evidence. Most people buying it in those years were relying on small, short trials and on the European experience with a specific pharmaceutical form — not on the kind of large independent trials that would come later. Sales figures are not quoted here because no source in the verified reference bank documents them.

The boom also had a consequence for public research: so many people were taking glucosamine that settling whether it worked became a public-health question, and a large publicly funded trial followed. That trial, GAIT, is described below.

Back to Table of Contents

1991 Onward: A Glucose Sensor That Causes Insulin Resistance

While glucosamine was becoming a joint supplement, diabetes researchers were finding a very different use for it. In 1991 S. Marshall, with V. Bacote and R. R. Traxinger at the University of Tennessee, published a paper whose title announced the "discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system."

They had found earlier that fat cells grown in the laboratory stopped responding properly to insulin only when three things were present together: glucose, insulin and glutamine. Glutamine is the amino-group donor for GFAT, so they suspected the glucosamine-making pathway. Two experiments supported the idea:

The interpretation that followed, now called the hexosamine hypothesis, is that a small share of incoming glucose is routed through this pathway as a fuel gauge. When too much glucose flows through it, the cell reads that as "fuel is plentiful" and turns down its response to insulin. Glucosamine is the one nutrient that bypasses the gate and floods the gauge directly, which is why it became a standard laboratory tool for producing insulin resistance.

In 2007 G. W. Hart, M. P. Housley and C. Slawson reviewed what that gauge does at the molecular level. The pathway's end product is attached to and removed from many proteins inside the cell as a tag called O-GlcNAc. Their review described this cycling as a nutrient and stress sensor that modulates cell signalling and noted emerging evidence that it has a role in diabetes and neurodegeneration.

Whether a supplement dose does the same thing in a living person has been tested many times, with mixed results; that evidence is weighed on Glucosamine, Blood Sugar and Diabetes.

Back to Table of Contents

The Trial Era and the Guidelines: 2001 to 2020

2001 — the Reginster trial. J.-Y. Reginster and colleagues randomised 212 people with knee osteoarthritis to 1,500 mg of glucosamine sulfate or placebo once daily for three years and measured the gap between the knee bones on X-ray. The 106 people on placebo lost a mean of 0.31 mm of joint space; the 106 on glucosamine sulfate showed no significant loss (0.06 mm). Symptoms also favoured glucosamine. The authors suggested it might be a disease-modifying agent, and this trial became the most-quoted evidence for glucosamine for years.

2006 — GAIT. The Glucosamine/chondroitin Arthritis Intervention Trial, funded by the US National Institutes of Health, was much larger. D. O. Clegg and colleagues randomised 1,583 people with painful knee osteoarthritis to 1,500 mg glucosamine daily, chondroitin, both, the anti-inflammatory drug celecoxib, or placebo for 24 weeks. Placebo alone produced a 20% pain reduction in 60.1% of people. Glucosamine did only 3.9 percentage points better, a difference that was not statistically significant; celecoxib did 10.0 points better. The authors concluded glucosamine and chondroitin, alone or together, did not reduce pain effectively in the overall group. An exploratory analysis hinted at benefit from the combination in the smaller moderate-to-severe pain subgroup — a hypothesis, not a finding, and not the trial's main result.

2010 — Wandel meta-analysis. S. Wandel and colleagues pooled 10 large trials with 3,803 patients. On a 10 cm pain scale, glucosamine beat placebo by just 0.4 cm, below the 0.9 cm they had set in advance as the smallest difference a patient would notice. Changes in joint space were minute. They also found that trials independent of industry showed smaller effects than commercially funded ones, and concluded that new prescriptions should be discouraged.

2017 — Roman-Blas trial. A six-month multicentre trial reported in its title that combined chondroitin sulfate and glucosamine sulfate "shows no superiority over placebo" for joint pain and function in knee osteoarthritis.

2019–2020 — the guidelines. The Osteoarthritis Research Society International (OARSI) 2019 guideline, built on systematic review of 60 treatments, does not recommend glucosamine. The 2019 American College of Rheumatology / Arthritis Foundation guideline, published in 2020, strongly recommends against glucosamine for knee and hip osteoarthritis, placing it among treatments the evidence did not support. Both guidelines instead put exercise and weight management at the centre of care. The full trial-by-trial picture is on Glucosamine for Joint Pain: What the Trials Found.

Back to Table of Contents

Worms, Mice and the UK Biobank Wave: 2014 to 2026

Just as the joint evidence was fading, a different line of research gave glucosamine new attention.

2014 — lifespan in worms and mice. S. Weimer, M. Ristow and colleagues reported that glucosamine extended the lifespan of the nematode worm C. elegans and of ageing mice. In worms it worked by impairing glucose use, which switched on the energy sensor AMPK and increased the building of new mitochondria. The mice showed more mitochondria, lower blood glucose and increased amino-acid breakdown. The authors described glucosamine as mimicking a low-carbohydrate diet. These were animal results and have not been shown in people.

2019 to 2026 — the UK Biobank studies. The UK Biobank enrolled about half a million British adults between 2006 and 2010 and asked them, among many questions, whether they regularly took glucosamine. Researchers have since linked those answers to health records:

StudyPeople analysedFinding in glucosamine users
Ma 2019, BMJ466,039 without heart diseaseLower risk of total cardiovascular events (hazard ratio 0.85) over a median of 7 years
Ma 2020, Diabetes Care404,508 without diabetesLower risk of new type 2 diabetes (hazard ratio 0.83) over a median of 8.1 years
Li 2020, Annals of the Rheumatic Diseases495,077; 19.1% reported regular useLower all-cause mortality (hazard ratio 0.85) over a median of 8.9 years
Hayward 2025, BMJ Open436,200More likely to be in a lower albuminuria (urine protein) group, odds ratio 0.81; a genetic (Mendelian randomisation) analysis found little evidence the link is causal
Zhang 2026, Journal of Integrative and Complementary Medicine54,096 with prediabetes or diabetesLower risk of cardiovascular events (hazard ratio 0.94) over a median of 10.56 years

These are striking associations, and they cut against the concern about blood sugar. They are reported here as they are. But they share the limits of all observational studies. Supplement use was self-reported once, at the start. People who choose to take a joint supplement may differ from those who don't in ways no adjustment fully captures — the healthy-user effect. And when Hayward and colleagues tried a genetic method designed to test cause and effect, they found little evidence for it and wrote that whether the relationship "is causal or confounded remains unclear." An association in a questionnaire is not the same as a benefit in a randomised trial, and the randomised trials of glucosamine for its main use were negative.

Back to Table of Contents

2026: Glucosamine Linked to Glucose Toxicity

The most recent chapter returns to Marshall's fuel gauge. In 2026 Y. Riahi, G. Leibowitz and colleagues asked what links high blood sugar to the damage it does to the insulin-making beta cells of the pancreas and to the kidney. Tracing labelled glucose in diabetic rodents, they found that tissue glucose levels correlated strongly with tissue glucosamine. A similar correlation with blood glucose held in humans with and without type 2 diabetes, and higher levels went with poorer beta-cell function.

In cells, low doses of glucosamine switched on mTORC1, a growth signal, through the O-GlcNAc tagging described above, and triggered oxidative stress, ER stress and loss of beta-cell identity. Blocking this axis in animals — genetically, or with the diabetes drug class SGLT2 inhibitors — eased beta-cell stress and improved glucose control. The authors identified the glucosamine/mTORC1 pathway as an important mediator of beta-cell and kidney dysfunction in diabetes.

An honest caveat: this study is about the glucosamine the body makes from excess glucose, not about supplements, and most of its mechanistic work was in animals and cells. It does not prove that a glucosamine pill harms people with diabetes. What it adds is another reason to think that glucosamine is not a neutral molecule for people whose blood sugar is already high.

Back to Table of Contents

Where Things Stand Today

A century and a half after Ledderhose, the picture is clearer than the supplement aisle suggests.

For joint health, the guideline-backed foundations are movement, strength training and a healthy weight, with whole foods that supply the raw materials — protein rich in glutamine and glycine, bone broth, and minerals such as magnesium. Whether glutamine itself is a better choice than glucosamine is examined on Glutamine Instead of Glucosamine?

Back to Table of Contents

Key Research Papers

The three historical papers were checked against their Crossref records; every other citation comes from a verified bank of PubMed records whose abstracts were read before any number from them was quoted. Findings from animals and cells are labelled as such in the text.

Chemistry and biochemistry

  1. Ledderhose G. Ueber salzsaures Glycosamin. Berichte der deutschen chemischen Gesellschaft. 1876;9(2):1200-1201. — doi:10.1002/cber.18760090251
  2. Ledderhose G. Ueber Glykosamin. Zeitschrift für physiologische Chemie. 1880;4(2):139-159. — doi:10.1515/bchm1.1880.4.2.139
  3. Haworth WN, Lake WHG, Peat S. The configuration of glucosamine (chitosamine). Journal of the Chemical Society. 1939:271. — doi:10.1039/jr9390000271
  4. Milewski S. Glucosamine-6-phosphate synthase—the multi-facets enzyme. Biochimica et Biophysica Acta. 2002;1597(2):173-192. — doi:10.1016/s0167-4838(02)00318-7 (PubMed PMID: 12044898)
  5. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. Journal of Biological Chemistry. 1991;266(8):4706-4712. — PubMed PMID: 2002019
  6. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446(7139):1017-1022. — doi:10.1038/nature05815 (PubMed PMID: 17460662)
  7. Riahi Y, Kogot-Levin A, Teselpapa Z, et al. Glucosamine links hyperglycemia to mTORC1 activation and glucose toxicity in diabetes. JCI Insight. 2026;11(10):e197331. — doi:10.1172/jci.insight.197331 (PubMed PMID: 42171606)
  8. Hawkinson TR, Liu Z, Ribas RA, et al. Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. 2026;8(6):1410-1425. — doi:10.1038/s42255-026-01538-4 (PubMed PMID: 42265388)

Absorption and blood levels

  1. Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 2001;51(9):699-725. — doi:10.1055/s-0031-1300105 (PubMed PMID: 11642003)
  2. Persiani S, Roda E, Rovati LC, et al. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis and Cartilage. 2005;13(12):1041-1049. — doi:10.1016/j.joca.2005.07.009 (PubMed PMID: 16168682)

Joint trials and guidelines

  1. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. The Lancet. 2001;357(9252):251-256. — doi:10.1016/S0140-6736(00)03610-2 (PubMed PMID: 11214126)
  2. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine. 2006;354(8):795-808. — doi:10.1056/NEJMoa052771 (PubMed PMID: 16495392)
  3. Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675. — doi:10.1136/bmj.c4675 (PubMed PMID: 20847017)
  4. Roman-Blas JA, Castañeda S, Sánchez-Pernaute O, et al. Combined treatment with chondroitin sulfate and glucosamine sulfate shows no superiority over placebo for reduction of joint pain and functional impairment in patients with knee osteoarthritis: a six-month multicenter, randomized, double-blind, placebo-controlled clinical trial. Arthritis & Rheumatology. 2017;69(1):77-85. — doi:10.1002/art.39819 (PubMed PMID: 27477804)
  5. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019;27(11):1578-1589. — doi:10.1016/j.joca.2019.06.011 (PubMed PMID: 31278997)
  6. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis & Rheumatology. 2020;72(2):220-233. — doi:10.1002/art.41142 (PubMed PMID: 31908163)

Lifespan, observational studies, blood sugar and safety

  1. Weimer S, Priebs J, Kuhlow D, et al. D-Glucosamine supplementation extends life span of nematodes and of ageing mice. Nature Communications. 2014;5:3563. — doi:10.1038/ncomms4563 (PubMed PMID: 24714520)
  2. Ma H, Li X, Sun D, et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ. 2019;365:l1628. — doi:10.1136/bmj.l1628 (PubMed PMID: 31088786)
  3. Ma H, Li X, Zhou T, et al. Glucosamine use, inflammation, and genetic susceptibility, and incidence of type 2 diabetes: a prospective study in UK Biobank. Diabetes Care. 2020;43(4):719-725. — doi:10.2337/dc19-1836 (PubMed PMID: 31988063)
  4. Li ZH, Gao X, Chung VC, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. Annals of the Rheumatic Diseases. 2020;79(6):829-836. — doi:10.1136/annrheumdis-2020-217176 (PubMed PMID: 32253185)
  5. Hayward SJ, Constantinescu A, Hazelwood E, et al. Association between glucosamine use and albuminuria in the UK: a cohort and Mendelian randomisation study. BMJ Open. 2025;15(11):e096344. — doi:10.1136/bmjopen-2024-096344 (PubMed PMID: 41271412)
  6. Zhang Z, Liu Y, Pan L, et al. Association of habitual glucosamine use with cardiovascular disease among individuals with prediabetes and diabetes: a prospective cohort study from the UK Biobank. Journal of Integrative and Complementary Medicine. 2026;32(8):659-667. — doi:10.1177/27683605261418094 (PubMed PMID: 41712318)
  7. Muniyappa R, Karne RJ, Hall G, et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes. 2006;55(11):3142-3150. — doi:10.2337/db06-0714 (PubMed PMID: 17065354)
  8. Pham T, Cornea A, Blick KE, et al. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. The American Journal of the Medical Sciences. 2007;333(6):333-339. — doi:10.1097/MAJ.0b013e318065bdbe (PubMed PMID: 17570985)
  9. Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy. 2008;28(4):540-548. — doi:10.1592/phco.28.4.540 (PubMed PMID: 18363538)

PubMed Topic Searches

  1. PubMed: Glucosamine and chitin history
  2. PubMed: The hexosamine pathway and insulin resistance
  3. PubMed: Randomised trials of glucosamine in knee osteoarthritis
  4. PubMed: Glucosamine in the UK Biobank
  5. PubMed: Glucosamine pharmacokinetics and bioavailability

This content is provided for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning or stopping any supplement.

Back to Table of Contents

Connections

Back to Table of Contents